Eli Lilly launches LillyDirect, opening the direct-to-consumer era

Eli Lilly's launch of LillyDirect in January 2024 opened a direct-to-consumer sales channel for its obesity medicines, letting people pay cash outside of insurance. Novo Nordisk followed with its own direct channel about a year later. Two years on, cash pricing has become a central feature of the GLP-1 market — including for the first weight-loss pill.

One caution about this report: the source material available here does not contain details about the LillyDirect launch itself, including its start date, the single-dose Zepbound vial prices, or the terms of Novo Nordisk's direct channel. Those specifics are not documented in the sources provided and are not repeated here. What the available reporting does show is where cash prices stand heading into 2026.

The current cash prices

Novo Nordisk won Food and Drug Administration approval in December 2025 for the first GLP-1 pill for weight loss, marketed as the Wegovy pill, and the company expected it to be widely available in January 2026 ^[1].

Novo Nordisk had not announced a list price for the pill as of that reporting, but said the two lowest doses would cost $149 a month for people paying cash without insurance ^[1]. The two higher doses were set at $299 a month for cash payers ^[1]. For people whose insurance covers the drug, out-of-pocket costs could be as low as $25 a month, according to the company ^[1].

For comparison, the lowest dose of the Wegovy injection costs $349 a month for cash payers ^[1]. Both Wegovy products are semaglutide.

A second pill, from Eli Lilly, was expected to gain FDA approval later in 2026 ^[1]. The source does not name that product or give a price.

What the trial data show

Dosing schedule matters for the oral version. The Wegovy pill must be taken every morning on an empty stomach, said Dr. Shauna Levy, medical director of the Tulane Weight Loss Center ^[1]. In a late-stage clinical trial, people who followed the schedule lost 16.6% of their body weight on average; that fell to 13.6% among people who did not take the pill exactly as prescribed ^[1].

"I think we need to consider that the efficacy of these medications is decreased if they are not taken consistently, and I am curious to see how they perform in real life," Levy said ^[1]. Lilly's pill still must be taken daily but can be taken at any time of day ^[1].

Dr. Daniela Hurtado Andrade, an endocrinologist at the Mayo Clinic in Jacksonville, Florida, said lower prices will most likely expand access, but noted that the biggest weight loss in trials came from the highest dose — meaning people seeking more weight loss would likely pay more ^[1]. Even $149 a month is too expensive for some people, she said ^[1].

Why it matters for patients

The direct-to-consumer channels changed how many Americans buy these drugs: instead of a pharmacy benefit deciding coverage, a person can pay a posted cash price. That makes list-versus-cash price differences a practical budgeting question rather than an abstract one. The numbers above show a wide spread — $25 a month with coverage, $149 or $299 a month cash for the pill, $349 a month cash for the lowest-dose injection ^[1].

The tiered cash pricing also ties cost to dose. Because the strongest weight loss in trials came at the highest doses, the cheapest tier may not match what a trial-level result required ^[1]. And with oral semaglutide, real-world results may differ from trial results if the morning, empty-stomach schedule is hard to keep ^[1].

What happens next

• January 2026: The Wegovy pill was expected to become widely available, with the higher-dose $299 cash price starting that month ^[1].
• Later in 2026: Lilly's weight-loss pill is expected to seek and potentially gain FDA approval ^[1].
• Also in the pipeline: Lilly's retatrutide, a weekly injection targeting GLP-1, GIP and glucagon, is nearing the end of clinical trials ^[1].